Factors restricting revenue growth of the global sickle cell disease treatment market
Lack of proper healthcare infrastructure in MEA: The healthcare industry in MEA is undergoing rapid changes. The lack of proper healthcare infrastructure in countries of Middle East and Africa may restrain the growth of the MEA sickle cell disease treatment market. Improper development and implementation of clinical practice guidelines and dearth of skilled labors in developing countries may also hinder the growth of the market.
Unavailability of drugs in rural areas: Unavailability of drugs in the several affected tribal regions of India is expected to hinder the market of sickle cell disease treatment market in India. The corruption in drug sales and low disposable income of majority sickle cell disease affected population in India is creating hindrance to the growth of the market.
Lack of reimbursement in Europe for sickle cell anemia treatment: Though sickle cell disease is responsible for many deaths every year, government or insurance companies still do not provide reimbursement for sickle cell anemia. Due to high cost associated with lifelong treatment of this disease and lack of reimbursement patients withdraw their treatment in between the dosage. The lack of reimbursement is expected to act as a hindrance to the growth of the disease.
High cost of treatment: The high cost associated with the treatment of sickle cell disease is expected to act as a hindrance to the growth of sickle cell disease market. Sickle cell disease treatment also requires alternate therapies such as blood transfusion and bone marrow transplant. Lack of reimbursements in this region for sickle cell disease treatment is expected to restrict the growth of the market.
Lack of FDA approved treatment for sickle cell disease: In North America, the U.S. FDA approved drugs for sickle cell anemia is only hydroxyurea and L-glutamine. The stringent FDA approval process for sickle cell disease drug approval is expected to hinder the growth of the market
With nearly 7% CAGR, sickle cell anemia segment by disease type to lead the global sickle cell disease treatment market
By indication, sickle cell anemia is expected to grab more than 50% revenue share and is likely to be valued more than US$ 190 Mn in 2017. Sickle Hemoglobin C disease is expected to be the lowest attractive drug type segment in sickle cell disease treatment market, with market attractiveness index of 0.5.
Global Sickle Cell Disease Treatment Market: Overview
The global sickle cell disease treatment market represents absolute $ opportunity of more than US$ 20 Mn in 2018 over 2017 and incremental opportunity of more than US$ 200 Mn between 2017 and 2025. Absolute $ opportunity is usually overlooked when analysts forecasts the market but, it is critical in assessing the level of opportunity that an enterprise can look to achieve, as well as to identify potential resources from both a sales and delivery perspective. With 6% of robust CAGR, this market is likely to see tremendous development during the projected period of 2017-2025.
Persistence Market Research has come up with a new report titled “Sickle Cell Disease Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025),” for the projected period of 8-years. According to this report, weighted average selling price has been considered to estimate the market size of various drugs mentioned in the scope of the study. We have not only captured the country price with the local currency but also the local currency figures is converted to USD to offer forecasts in a consistent currency standard. Furthermore, we have also considered the latest annual exchange rate to reflect the impact of the most recent economic conditions of country. Prices considered in the models are standardized based on the average dosage used per Sickle cell disease treatment per dosage in a year. Availability of branded off-patent equivalents have been taken into consideration while calculating prices.
We have used following parameters to estimate the global market size
Market sizing is done using our in-house epidemiology data based model to estimate sickle cell disease treatment market. We adopt bottom-up approach to forecast sickle cell disease treatment market globally. The following parameters are used to estimate the market size for the base year 2016:
We have used a number of sources to present a detailed analysis of the global sickle cell disease treatment market
Our research methodology uses both primary and secondary research to collect the relevant data. We have analyzed the market by considering the revenue through extensive primary research to understand the usage pattern, historic trends, and problems faced by the physicians, the required treatment developments, and most preferred drugs. Key opinion leaders were considered for the primary research that included experienced healthcare professionals in various healthcare facilities at country level. These estimates were further validated with drug manufacturers, distributors, and suppliers.
Extensive secondary research has been carried out to understand the epidemiology of sickle cell disease, treatment rate, adoption rate, regulatory scenarios, average selling price, reimbursement scenario, by referring published scientific literature from various databases such as the WHO, National Heart, Lung, and Blood Institute (NHLBI), PubMed, Springer, and Wiley among many others. We have also analyzed various companies’ annual report, investor presentation, SEC filings, 10k reports_bk_01_01_2020 and press release operating in sickle cell disease treatment market to fetch substantial information about the market size, trends, opportunity, drivers, and restraints to analyze key players.
Report Inclusions and Exclusions
In this report, we have considered only those drugs that are administered for sickle cell disease treatment. The study includes drugs such as hydroxyurea, antibiotics, pain-relieving medications and others. The drugs considered in others segments are drugs that are administered based on patients conditions and also includes the newly FDA approved drug L-Glutamine for sickle cell disease treatment.
We have not included other therapies such as surgeries, blood transfusions, gene therapies and bone marrow transplantation etc. to calculate market value in this study. The market also do not includes any products from the drug type segment administered to patients of any other indications. The market value is calculated based on only the drug type (Hydroxyurea, Antibiotics, Pain-relieving medications, and other drugs) administered for sickle cell disease treatment.
Forecast Assumptions and Limitations
To forecast the market we have considered the following assumptions:
Our clients should note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting is done on our internal proprietary model which also uses different macro-economic factors and industry based demand driving factors that are impacting the market and its forecast trends apart from disease related factors.